Clinical trials: Steroid Refractory GVHD
Chronic Graft vs Host Disease
Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease
A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in patients who do not obtain complete remission with ruxolitinib
- Trial name
- GVHD-TReG (NCT03683498)
- Testing
- Regulatory T-cell enriched infusion
- Where
- Spain
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Graft Versus Host Disease
High-Dose Cyclophosphamide for Steroid Refractory GVHD
RATIONALE: High-dose cyclophosphamide may be an effective treatment for acute graft-versus-host disease that did not respond to steroid therapy.
- Trial name
- NCT00492921
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Graft-versus-Host Disease
Universal CNK-UT Therapy for Refractory aGVHD
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of universal T-cells engineered with chimeric…
- Trial name
- CNK-UT (NCT06750133)
- Testing
- Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
- Where
- 2 sites in China
- Volunteers
- 23 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Corticosteroid Refractory Acute Graft vs Host Disease
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.
- Trial name
- REACH2 (NCT02913261)
- Testing
- Ruxolitinib (RUX), Best Available Therapy (BAT)
- Where
- 103 sites in Australia, Austria and 20 more
- Volunteers
- 310 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF)
Managed Access Programs for INC424, Ruxolitinib
The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib
- Conditions
- Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF), Severe/Very Severe COVID-19 Illness
- Trial name
- NCT04745637
- Testing
- Ruxolitinib
- Sponsor
- Novartis Pharmaceuticals
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
The purpose of this study was to assess the efficacy of ruxolitinib in combination with corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD).
- Trial name
- NCT02953678
- Testing
- Ruxolitinib, Prednisone or methylprednisolone
- Where
- 38 sites in United States
- Volunteers
- 71 people
- Sponsor
- Incyte Corporation
Graft Versus Host Disease
Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD
Graft versus host disease is a serious and often life-threatening complication in allogeneic haematopoietic stem cell transplantation.
- Trial name
- NCT02824653
- Testing
- Mesenchymal Stem Cells
- Where
- Pakistan
- Volunteers
- 10 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
GVHD
Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)
The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal aGVHD.
- Trial name
- NCT05415410
- Testing
- Apraglutide
- Where
- 13 sites in United States, Germany and 2 more
- Volunteers
- 31 people
- Sponsor
- VectivBio AG
Steroid-refractory Acute Graft-versus-host Disease
Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy
The primary purpose of this trial is to demonstrate the superiority of MC0518 compared to the first used best available therapy (BAT) with respect to overall response rate (ORR) at Day 28 and/or overall survival (OS) until Visit…
- Trial name
- IDUNN (NCT04629833)
- Testing
- MC0518, BAT
- Where
- 42 sites in France, Germany and 3 more
- Volunteers
- 210 people
- Sponsor
- medac GmbH
Graft-versus-host-disease
Treatment of Steroid Resistant GVHD by Infusion MSC
For numerous malignant diseases allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy. One of the major complications is the occurrence of acute graft-versus-host-disease (aGVHD).
- Trial name
- MSCforGVHD (NCT00827398)
- Testing
- MSC (hPPL)
- Where
- 2 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- N.M. Wulffraat
GVHD,Acute, Stem Cell Transplant Complications
MAP-guided Preemptive Therapy of aGvHD
Acute graft versus host disease (aGvHD) is a severe and potentially fatal complication of allogeneic hematopoietic stem cell transplantation (HCT).
- Trial name
- NCT05368181
- Testing
- Methylprednisolone
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Sichuan University
Acute Graft Versus Host Disease
Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD
Phase II efficacy evaluation, phase I/II efficacy and toxicity trial of recombinant human keratinocyte growth factor for the treatment of steroid refractory gastrointestinal graft versus host disease.
- Trial name
- NCT00038792
- Testing
- Recombinant Human Keratinocyte Growth Factor
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
GVHD, Acute Stem Cell Transplant Complications
MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib
The goal of this observation study is to test in patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT).
- Trial name
- NCT06075225
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sichuan University
Steroid Refractory GVHD
Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD
A Phase 3, Multicenter, open label, study to Evaluate the EFficacy and SaFEty of Leukotac® (inolimomab) in pediatric patients with steroid resistant acute Graft versus Host Disease (SR-aGvHD)
- Trial name
- EiFFEL (NCT04289103)
- Testing
- Inolimomab (Leukotac)
- Volunteers
- 65 people
- Sponsor
- ElsaLys Biotech
Hematological Malignancy, GVHD - Graft-Versus-Host Disease
Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease.
Study Design Prospective, single center, single arm, Phase II study. Research aims and objectives Aim: To evaluate the efficacy and safety of standardized Withaferin A in steroid refractory acute GvHD in patients post allogeneic…
- Conditions
- Hematological Malignancy, GVHD - Graft-Versus-Host Disease, Steriod Refractory
- Trial name
- Withaferin_A (NCT07708987)
- Testing
- Standardized Withaferin A (SWA)
- Where
- India
- Volunteers
- 34 people
- Sponsor
- Tata Memorial Centre
Steroid-refractory Acute Graft-versus-host Disease
Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease
The purpose of this trial is the comparative evaluation of overall response rate (ORR) in paediatric participants with steroid-refractory acute graft-versus-host disease (SR-aGvHD) at Visit Day 28 after treatment with MC0518 or…
- Trial name
- BALDER (NCT06075706)
- Testing
- MC0518, BAT
- Where
- 36 sites in France, Germany and 3 more
- Volunteers
- 49 people
- Sponsor
- medac GmbH
Steroid Refractory GVHD
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Steroid-refractory graft-vs-host disease (SR-GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT05663827
- Testing
- Ruxolitinib
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Yi-Lun Wang
Chronic Graft-versus-host Disease
Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children
In this study we will combine mycophenolate mofetil and imatinib mesylate to treat steroid-refractory sclerotic/fibrotic type chronic graft-versus-host disease (GVHD) to see the response rate and to find the safety of combination.
- Trial name
- NCT01898377
- Testing
- Imatinib mesylate, Mycophenolate mofetil
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Seoul National University Hospital
Graft vs Host Disease
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
This is a prospective, multicenter, randomized controlled trial designed to evaluate whether the combination of ruxolitinib and etanercept provides superior efficacy compared with ruxolitinib monotherapy in patients with severe…
- Trial name
- RESCUE (NCT07184853)
- Testing
- Ruxolitinib (JAKAVI®), Etanercept (Enbrel)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- First Affiliated Hospital of Zhejiang University